The Steering Group act as the governance to the CDT. The group consists of world class research leaders who will provide feedback and guidance to refine the CDT processes and drive forward change when needed.
Dr John Sinden (Committee Chair)
GlialignDr John Sinden is one of the founders and Chief Executive Officer of Glialign. He is currently optimising a method for producing a living nerve growth guide designated “EngNT”, which is intended as an ‘off-the-shelf’ nerve replacement – primarily for peripheral nerve repair. This represents an innovative engineering solution to an unmet clinical need.
Dr Damien Marshall
Cell and Gene Therapy CatapultDr Damien Marshall is the Director of New Technology at Cell and Gene Therapy Catapult. He is an enthusiastic and motivated bioindustry professional with over 15 years experience leading research and development teams working on products at all stages of clinical development in the cell and gene therapy sector.
Dr Annette Bramley
N8 Research PartnershipDr Annette Bramley is the Director of N8 Research Partnership. She is a highly motivated and experienced executive leader skilled in orchestrating strategy and excellence for research in complex organisations. She partners with the leadership of the top research universities in the North of England, coordinating funding for research and education programme grants across a wide range of disciplines based on excellence and adding value. She also has an extensive history of delivering results in roles with the Engineering and Physical Sciences Research Council (EPSRC), particularly in the area of Healthcare Technologies.
Prof Andres Garcia FBSE
Georgia TechProf Andres Garcia is the Executive Director at Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Institute of Technology. His research program centers on integrating innovative engineering, materials science, and cell biology concepts and technologies to generate (i) novel insights into the regulation of adhesive forces and mechanotransduction, and (ii) biofunctional materials (hydrogels, coatings, nanoparticles) for protein/cell delivery and tissue repair. This cross-disciplinary effort has resulted in new biomaterial platforms that elicit targeted cellular responses and tissue repair in various biomedical applications (bone repair, therapeutic vascularization, pancreatic islet delivery, and infection), innovative technologies to study and exploit cell adhesive interactions, and new mechanistic insights into the interplay of mechanics and cell biology.
Prof Molly Stevens FREng FRS
Imperial CollegeMolly Stevens is Professor of Biomedical Materials and Regenerative Medicine and the Research Director for Biomedical Material Sciences in the Department of Materials, Department of Bioengineering and the Institute of Biomedical Engineering at Imperial College London. Molly leads a large and extremely multidisciplinary research group of students and postdocs/fellows. The group is focused on both high quality fundamental science and translation for human health. Research in regenerative medicine within her group includes the directed differentiation of stem cells, the design of novel bioactive scaffolds and new approaches towards tissue regeneration. She has developed novel approaches to tissue engineering that are likely to prove very powerful in the engineering of large quantities of human mature bone for autologous transplantation as well as other vital organs such as liver and pancreas, which have proven elusive with other approaches.
EPSRCKaren is the Portfolio Manager for the Synthetic Biology and Biomaterials & Tissue Engineering Research Areas at EPSRC. She has a background in Applied Chemistry, industrial product development and Secondary School teaching.